Immunohistochemical analysis of xenograft tumors revealed that IGF2BP2 knockdown promoted redifferentiation, as evidenced by a concomitant significant increase in the differentiation marker SLC5A5 (NIS) with a marked reduction in the cancer stem cell marker CD133, compared to shNC controls (Fig. 3N-O). Here, IGF2BP2 is linked to cancer.